Northwest Bioth Cmn (NWBO): Price and Financial Metrics


Northwest Bioth Cmn (NWBO)

Today's Latest Price: $0.34 USD

0.01 (-2.02%)

Updated May 29 5:20pm

Add NWBO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

NWBO Stock Summary

  • NWBO's price/sales ratio is 91.52; that's higher than the P/S ratio of 97.42% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.28 for Northwest Biotherapeutics Inc; that's greater than it is for just 6.44% of US stocks.
  • As for revenue growth, note that NWBO's revenue has grown 484.95% over the past 12 months; that beats the revenue growth of 98.64% of US companies in our set.
  • Stocks that are quantitatively similar to NWBO, based on their financial statements, market capitalization, and price volatility, are XERS, KPTI, ACUR, ATNX, and INSM.
  • Visit NWBO's SEC page to see the company's official filings. To visit the company's web site, go to www.nwbio.com.
NWBO Daily Price Range
NWBO 52-Week Price Range

NWBO Stock Price Chart More Charts


NWBO Price/Volume Stats

Current price $0.34 52-week high $0.42
Prev. close $0.35 52-week low $0.14
Day low $0.32 Volume 2,800,499
Day high $0.36 Avg. volume 2,032,267
50-day MA $0.19 Dividend yield N/A
200-day MA $0.21 Market Cap 234.33M

Northwest Bioth Cmn (NWBO) Company Bio


Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.


NWBO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NWBO Latest Social Stream


Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about Northwest Biotherapeutics Inc that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

Did Northwest Biotherapeutics Just Check Off 1 Box Needed for Its Stock to Double?

Will a 14-year clinical trial evaluating an immunotherapy for the most lethal form of brain cancer have a positive outcome?

Yahoo | May 28, 2020

NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers, will discuss the projected schedule for reaching data lock, unblinding and reporting of top line data from its 331-patient Phase 3 trial of DCVax®-L for Glioblastoma brain cancer at the Company's 2019 Annual Meeting. The Meeting is being held virtually due to the current public health crisis.

Yahoo | April 18, 2020

NW Bio Announces Annual Shareholders' Meeting Scheduled for April 18, 2020

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the 2019 Annual Shareholder's Meeting will be held on April 18, 2020, at 1:00 pm in Washington, DC.

Yahoo | February 18, 2020

Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has further expanded its senior management team with the addition of Ms. Jean M. Davis as Chief Financial Officer, Chief Accounting Officer, and interim Chief Information Officer.

Yahoo | December 12, 2019

Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, is presenting at 11:40 a.m. today at the inaugural Glioblastoma (GBM) Drug Development Summit being held at the Westin Boston Waterfront Hotel in Boston, Massachusetts.

Yahoo | December 11, 2019

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo 100.00%
3-mo 74.36%
6-mo 52.13%
1-year 4.45%
3-year 85.79%
5-year -96.18%
YTD 58.21%
2019 4.57%
2018 -12.63%
2017 -32.43%
2016 -89.12%
2015 -40.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1748 seconds.